MAPT and Alzheimer disease: However, to date, only one study has evaluated the diagnostic value of early‐phase amyloid PET to differentiate between CAA and AD [12] and no studies have yet evaluated the relationship between dual‐phase PiB and concomitant tau pathology in patients with CAA.